Dear MRI Insider,
AuntMinnie.com is pleased to present a fascinating primer on the latest advances in targeted MR contrast agents. Contributing writer Michael Tweedle, Ph.D., is a council director of the Society of Non-Invasive Imaging in Drug Development (SNIDD), an institute of the Academy of Molecular Imaging (AMI).
In Part I of this two-part article, Tweedle, who is also president of Bracco Research USA in Princeton, NJ, discusses the potential impact of biochemically targeted MRI agents in ramping up drug development, and, eventually, in providing more effective cancer treatments. As an MRI Insider subscriber, you can enjoy this article before our other members can access it. Click here for the details.
When you're finished reading, be sure to come back to the MRI Digital Community on Friday for Part II, in which Tweedle will tackle targeted MRI agents currently in development, such as fibrin-binding Gd chelates.
In the meantime, check out our recent articles on fetal lung imaging, breast MR following lumpectomy, and the value of diffusion-weighted imaging for managing subacute stroke.
